Mammary‐analog secretory carcinoma in children: Surgery or TRK inhibitors first?
Copyright policy )Mammary‐analog secretory carcinoma in children: Surgery or TRK inhibitors first?
AbstractWe report two cases of pediatric mammary‐analog secretory carcinoma (MASC), a male operated on at age 8 and a female operated on at 12, who are in remission 2 years after surgery. The diagnosis of MASC was challenging and established by identifying theETV6::NTRK3fusion transcript in both cases. Given the excellent results of TRK inhibitor treatments in adult MASC and pediatric tumors expressing anETV6::NTRK3fusion, they should probably be prescribed as first‐line treatment in cases requiring surgery with foreseeable serious sequelae or metastatic disease.
mammary analog secretory carcinoma, [SDV] Life Sciences [q-bio], NTRK fusion, entrectinib, larotrectinib, TRK inhibitor
mammary analog secretory carcinoma, [SDV] Life Sciences [q-bio], NTRK fusion, entrectinib, larotrectinib, TRK inhibitor
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).4 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!